Profile data is unavailable for this security.
About the company
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2010
- Employees1.00
- LocationAptorum Group Ltd17 Hanover SquareLONDON W1S 1BNUnited KingdomGBR
- Phone+44 208 092 9299
- Fax+44 203 928 8277
- Websitehttps://www.aptorumgroup.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bullfrog AI Holdings Inc | 116.67k | -6.76m | 5.91m | 9.00 | -- | 2.78 | -- | 50.66 | -0.6936 | -0.6936 | 0.0119 | 0.1866 | 0.0319 | -- | -- | 12,963.33 | -184.34 | -- | -233.50 | -- | 18.76 | -- | -5,770.66 | -- | -- | -- | 0.0278 | -- | -100.00 | -- | -31.42 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -25.62m | 5.95m | 28.00 | -- | 0.828 | -- | -- | -9.62 | -9.62 | 0.00 | 1.00 | 0.00 | -- | -- | 0.00 | -194.84 | -- | -1,279.90 | -- | -- | -- | -- | -- | -- | -58.24 | 0.1544 | -- | -- | -- | 18.49 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 6.07m | 1.00 | -- | 2.14 | -- | 1,011.76 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.97m | 6.13m | 37.00 | -- | 0.1834 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Mustang Bio Inc | 0.00 | -2.34m | 6.23m | 6.00 | -- | 0.638 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -10.85m | 6.29m | 27.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.6973 | 0.00 | -- | -- | 0.00 | -637.06 | -112.30 | -- | -219.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.39 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.29m | -10.87m | 6.69m | 16.00 | -- | 1.38 | -- | 2.03 | -17.27 | -17.27 | 5.09 | 3.98 | 0.3025 | 2.74 | 5.08 | 205,752.50 | -100.21 | -73.55 | -191.77 | -123.30 | 43.08 | -- | -331.26 | -476.22 | 0.7618 | -- | 0.0392 | -- | -1.90 | 74.49 | -4.06 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 6.00k | -5.96m | 6.74m | 4.00 | -- | 0.8907 | -- | 1,124.12 | -2.87 | -2.87 | 0.0027 | 2.17 | 0.0009 | 1.10 | -- | 1,500.00 | -93.58 | -83.62 | -98.14 | -- | 60.00 | 62.58 | -99,356.66 | -10,541.10 | 20.70 | -- | 0.00 | -- | 22.22 | -41.85 | -3.91 | -- | -- | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.83m | 1.00 | -- | 0.2661 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -26.19m | 6.92m | 22.00 | -- | 0.2967 | -- | -- | -5.53 | -5.53 | 0.00 | 0.6539 | 0.00 | -- | -- | 0.00 | -73.83 | -37.94 | -99.55 | -42.02 | -- | -- | -- | -- | -- | -- | 0.2025 | -- | -- | -- | -39.81 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 6.96m | 37.00 | -- | 0.3079 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Synlogic Inc | 0.00 | -3.23m | 7.17m | 1.00 | -- | 0.6949 | -- | -- | -0.2625 | -0.2625 | 0.00 | 0.8826 | 0.00 | -- | -- | 0.00 | -17.30 | -44.41 | -27.54 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Alzamend Neuro Inc | 0.00 | -6.47m | 7.30m | 4.00 | -- | 1.67 | -- | -- | -5.71 | -5.71 | 0.00 | 1.15 | 0.00 | -- | -- | 0.00 | -116.49 | -171.97 | -144.76 | -256.71 | -- | -- | -- | -- | -- | -766.93 | 0.00 | -- | -- | -- | 48.68 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.75m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| L1 Capital Global, Inc.as of 30 Apr 2025 | 383.75k | 6.05% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 5.50k | 0.09% |
| UBS Securities LLCas of 31 Dec 2025 | 2.25k | 0.04% |
| Citigroup Global Markets, Inc. (Investment Management)as of 30 Sep 2025 | 277.00 | 0.00% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 7.00 | 0.00% |
| Geode Capital Management LLCas of 30 Sep 2025 | 0.00 | 0.00% |
